20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina

20/20 BioLabs has entered into an exclusive worldwide licensing agreement with the University of South Carolina to commercialize a patented algorithm designed to identify aggressive prostate tumors earlier. The algorithm analyzes changes in prostate-specific antigen (PSA) levels over time, allowing for early detection and intervention of dangerous prostate cancers. This technology will be integrated into 20/20’s OneTest for Cancer platform and made available to other clinical labs worldwide.